FDA's Warning on Ixchiq Vaccine for Chikungunya

The FDA and CDC have recommended pausing the use of the Ixchiq vaccine for chikungunya in adults over 60 due to fatal complications. The vaccine, approved for those aged 18 and older, has caused serious adverse events, including deaths, in older adults.